Rhus (Somagh)

Phase 1Small molecule

SShiraz University of Medical Sciences

Rhus (Somagh) is one of 36 small molecule programs targeting Hyperlipidemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperlipidemiaActive, not recruiting

HyperlipidemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

97 competitors in Hyperlipidemia

#DrugCompanyPhaseTrials

Repatha

Amgen

Phase 3

3 2

Avapro

Sanofi

Phase 3

2 3

Lorelco

Sanofi

Phase 3

1 4

Praluent

Regeneron

Phase 3

1 5

Micardis

Boehringer Ingelheim

Phase 3

3 6

Lesinurad

EEsperion Therapeutics, Inc.

Phase 3

2 7

Reyataz

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 8

Zocor

OOrganon and Co

Phase 3

1 9

Tricor

JJagotec

Phase 3

1 10

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Body Weight1 trial

The Effects of Rhus Coriaria L. on Body Weight

Completed·SShiraz University of Medical Sciences·N/A·NCT02754089·50 enrolled

Hyperlipidemia1 trial

The Effects of Rhus Coriaria L. on Serum Lipid Levels of Patients With Hyperlipidemia

Completed·SShiraz University of Medical Sciences·Phase 1·NCT02295293·74 enrolled

Uric Acid1 trial

The Effects of Rhus Coriaria L. on Serum Uric Acid Levels

Unknown status·SShiraz University of Medical Sciences·N/A·NCT02891031·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Rhus (Somagh). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rhus (Somagh) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rhus (Somagh). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shiraz University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShiraz University of Medical Sciences

Rhus (Somagh)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Body Weight1 trial

Hyperlipidemia1 trial

Uric Acid1 trial

References

Drug Info

Quick Facts

Related News